Virginia Tech subheader


breast cancer awareness ribbon



Protein activators and inhibitors of blood clotting modulate platelet-mediated coagulation. Manipulating activity of these molecules is one of the major targets to control undesired effects that occur with blood clotting. Virginia Tech scientists have identified a novel protein target for intervention in thrombosis.  It is a platelet aggregation inhibitor that specifically binds and modulates the progression of platelet–mediated coagulation. Expression of this inhibitory protein is restricted to platelets, some tumor cell types, and very early stages of embryogenesis, so small molecules or other therapeutics can be tailored to intervene in a very target-specific manner.





  • Downregulation of haemostasis in patients prone to various diseases ranging from stroke to heart disease

  • Controlling bleeding during surgery

  • Pro- or anti-thrombotic modulation to restore haemeostasis

  • The technology targets a specific molecule released in response to platelet activation.

  • The targeted system is inherently reversible.

  • Intervention can be tightly regulated to increase or decrease thrombosis

  • Various routes of administration are possible.



Antithrombotic drugs often fail in the long run due to the emergence of significant compliance and safety issues, including increased bleeding.  Thus, this new technology is unique in that it targets a specific molecule that is released in response to platelet activation and otherwise remains intracellular.  Analogs can be delivered in a nanoparticle-based system to provide high stability, higher carrier capacity, selective release, and feasibility of incorporation of hydrophobic molecules. This approach will allow drug delivery by variable routes of administration, including oral and inhalation.

An important concern about antithrombotic drugs is how to reverse their effects in the event of bleeding.  The inherent reversibility of our molecule system allows the design of a counter-regulatory intervention.  Drug-based nanoparticles can also be designed to allow controlled (sustained) drug release from the matrix, thus avoiding numerous secondary or side effects caused by accumulation of residual drug in the body.

For more information about this product, or to discuss licensing terms, please contact Jackie Reed with Virginia Tech Intellectual Properties at 540/443-9217, or

Click here to read a Virginia Tech article entitled "Control of blood clotting by platelets described; provides medical promise" (November 24, 2009).

Virginia Tech Intellectual Properties, Inc.
2200 Kraft Drive, Suite 1050
Blacksburg, VA 24060

Phone (540) 951-9374
Fax (540) 951-5292


Dr. Carla V. Finkielstein is an associate professor in the biological sciences department at Virginia Tech. She is a cell and molecular biologist with a strong background in signal transduction. Finkielstein is also a trained biochemist with extensive experience in protein chemistry and biophysical techniques.

Dr. Daniel G.S. Capelluto is an associate professor in the biological sciences department at Virginia Tech. He has extensive experience has vast experience working with protein domains using multidimensional NMR spectroscopy.. His research group indentifies binding sites at atomic resolution and executes SPR experiment.

Last Update 20 February 2015